Intense Peptide Summer is just around the corner.
In a two-day marathon hearing that pitted career regulatory representatives against peptide industry figures, the Food and Drug Administration voted on July 23 and 24 to recommend approval of six peptides that were previously banned for human use under the Biden administration.
By the end of the day Friday, the FDA panel had recommended approval of six of the seven peptides up for debate. That list includes the buzzy “Wolverine Stack” made up of BPC-157 and TB-500, peptides that have been used by biohackers and other pioneers of the gray market to heal skin, ligaments muscles and bones, as well as KPV, said to treat an inflammatory skin condition, MOTS-c, used to treat metabolic conditions, amidaltide, a sleep aid, and Semax is a predictable form of migraine relief. Only epitalon, a peptide that has been used to reduce insomnia, was rejected by the panel.
These recommendations could open the door to a potentially billion-dollar peptide industry in the US, where peptides are already a buzzword among wellness influencers, Hollywood and the manosphere. Himes, a telehealth company that sells direct-to-consumer finasteride and GLP-1s, has indicated that it will take steps to sell the controversial substances once they are approved after acquiring a peptide manufacturing facility. in 2025.
Controversy arose within the FDA even before the hearing began. Last spring, several officials inside the agency expressed concern According to the report, then-FDA head Marty Zakari was holding a hearing with panelists who had direct ties to the peptide industry. Washington Post Published last week. As this was happening, career FDA scientists quietly argued in posts shared on FDA website There have not yet been enough clinical human trials to confirm that the peptides in question are both safe and effective for compounding and distribution to pharmacies. Then, in the days before the hearing, controversy surrounding these new industry-related panelists prompted the FDA to add again 8 new experts joined the hearing, bringing the total number of voting individuals to 14.
This tension between established regulatory medicine and the billion-dollar wellness industry was on full display throughout the hearing. In the first vote, six peptide suppliers, along with a pharmaceutical executive and a compounding pharmacist, approved peptide BPC-157 by an 8-6 vote.
Peptides are chains of amino acids, which are the building blocks of proteins, and work as messengers for the body’s cells. They play major roles in hormonal regulation, skin health, and your immune system. Already regulated and FDA-approved peptides include insulin and GLP-1s, but the current craze surrounding the drug extends far beyond these more well-researched examples. For example, BPC-157 has not yet been the subject of intensive human clinical trials, despite its popularity among tech industry grindsetters, longevity bros, and Pilates girls. “This is not the traditional way that the FDA works, they usually go through phase one trial, phase two trial, phase three trial and that takes years,” says Dr. Katie Rizzone, a sports medicine expert at the University of Rochester. “I don’t see any evidence at this point.”
At least one representative of the telehealth industry agreed that there was little data to support the claims for BPC-157. “I’m not going to tell you that the evidence for BPC-157 is strong,” Dr. Ananth Vinjamoori, chief medical officer of Hims, told the panel during his testimony. “It is not, and I will not insist on it.” Still, Himes’ stock soared 13% After the first day of panels.
